← Back to Clinical Trials
Recruiting Phase 2 NCT06376734

Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

Trial Parameters

Condition Major Depressive Disorder
Sponsor Brigham and Women's Hospital
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 180
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2025-01-30
Completion 2029-06-01
Interventions
Transcranial magnetic stimulation

Brief Summary

Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.

Eligibility Criteria

Inclusion Criteria: * Age 18-65 * English proficiency sufficient for informed consent, questionnaires/tasks, and treatment * Primary diagnosis of one of the following: major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), or schizophrenia (determined by focal assessment using the Structured Clinical Interview for DSM-5) * ≥20 on the Beck Depression Inventory for patients with MDD * ≥16 on the Beck Anxiety Inventory for patients with GAD * ≥16 on the Yale-Brown Obsessive-Compulsive Scale for patients with OCD * ≥58 on the Positive and Negative Symptom Scale for patients with schizophrenia * Stable psychotropic medication regimen, or remain medication free, for 4 weeks prior to treatment (Medication changes during study enrollment period will be tracked for post hoc analysis). * Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial Exclusion Cr

Related Trials